PL3512506T3 - Zastosowanie pridopidyny w leczeniu zespołu retta - Google Patents

Zastosowanie pridopidyny w leczeniu zespołu retta

Info

Publication number
PL3512506T3
PL3512506T3 PL17851614T PL17851614T PL3512506T3 PL 3512506 T3 PL3512506 T3 PL 3512506T3 PL 17851614 T PL17851614 T PL 17851614T PL 17851614 T PL17851614 T PL 17851614T PL 3512506 T3 PL3512506 T3 PL 3512506T3
Authority
PL
Poland
Prior art keywords
pridopidine
rett syndrome
treating rett
treating
syndrome
Prior art date
Application number
PL17851614T
Other languages
English (en)
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3512506T3 publication Critical patent/PL3512506T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL17851614T 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta PL3512506T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
EP17851614.2A EP3512506B1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (1)

Publication Number Publication Date
PL3512506T3 true PL3512506T3 (pl) 2022-05-30

Family

ID=61619744

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta
PL22150695.9T PL4005570T3 (pl) 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL22150695.9T PL4005570T3 (pl) 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta

Country Status (13)

Country Link
EP (2) EP3512506B1 (pl)
JP (1) JP6977029B2 (pl)
CN (1) CN109982686A (pl)
AU (1) AU2017326013B2 (pl)
BR (1) BR112019005040A2 (pl)
CA (1) CA3036984C (pl)
DK (2) DK3512506T3 (pl)
ES (2) ES2986807T3 (pl)
HU (1) HUE058314T2 (pl)
IL (1) IL265342B2 (pl)
MX (1) MX388845B (pl)
PL (2) PL3512506T3 (pl)
WO (1) WO2018053280A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3010506T3 (da) 2013-06-21 2021-07-12 Prilenia Neurotherapeutics Ltd Pridopidin i behandling af huntingtons sygdom
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
DK3504187T3 (da) 2016-08-24 2025-04-14 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af funktionel tilbagegang
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2020218158B2 (en) 2019-02-04 2023-08-03 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
PL1802573T3 (pl) 2004-10-13 2017-03-31 Teva Pharmaceuticals International Gmbh Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny
WO2012028635A1 (en) 2010-09-03 2012-03-08 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX347209B (es) * 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
DK3010506T3 (da) 2013-06-21 2021-07-12 Prilenia Neurotherapeutics Ltd Pridopidin i behandling af huntingtons sygdom
EA201691454A1 (ru) 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
US10603311B2 (en) * 2015-02-25 2020-03-31 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
AU2017326013A1 (en) 2019-04-11
PL4005570T3 (pl) 2024-09-23
BR112019005040A2 (pt) 2019-07-16
CN109982686A (zh) 2019-07-05
JP2019532926A (ja) 2019-11-14
WO2018053280A1 (en) 2018-03-22
EP3512506A1 (en) 2019-07-24
MX388845B (es) 2025-03-20
CA3036984A1 (en) 2018-03-22
EP4005570B1 (en) 2024-05-15
DK4005570T3 (da) 2024-08-19
HUE058314T2 (hu) 2022-07-28
EP3512506B1 (en) 2022-01-26
CA3036984C (en) 2023-07-18
DK3512506T3 (da) 2022-04-19
IL265342A (en) 2019-05-30
JP6977029B2 (ja) 2021-12-08
EP3512506A4 (en) 2020-05-27
IL265342B2 (en) 2023-06-01
AU2017326013B2 (en) 2020-12-24
ES2909557T3 (es) 2022-05-09
ES2986807T3 (es) 2024-11-12
EP4005570A1 (en) 2022-06-01
MX2019003069A (es) 2019-09-02

Similar Documents

Publication Publication Date Title
IL259560A (en) Inhibitors of the menin-mll interaction
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
ZA201606610B (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL247515A0 (en) Snekribirock for the treatment of leprosy
IL265342A (en) Use of pridofidine for the treatment of Rett syndrome
ZA201706257B (en) Treatment of wood
IL257061A (en) Inhibitors of ezh2
SI3506904T1 (sl) Zdravljenje demence
IL259856A (en) A preparation for the treatment of Crigler-Najjar syndrome
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
PT3122349T (pt) Composições para o tratamento da autodigestão
IL251350A0 (en) Treatment of Rett syndrome
GB201412010D0 (en) Treatment of hypertransaminasemia
IL262547A (en) Methods and compositions for treatment of rett syndrome
HK40009961A (en) Use of pridopidine for treating rett syndrome
EP3122187A4 (en) Treatment of rett syndrome